Kenvue (NYSE:KVUE) Price Target Cut to $23.00 by Analysts at Deutsche Bank Aktiengesellschaft

Kenvue (NYSE:KVUE) had its price target decreased by Deutsche Bank Aktiengesellschaft from $24.00 to $23.00 in a research report sent to investors on Thursday, Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on the company. Citigroup decreased their price objective on Kenvue from $21.00 to $20.00 and set a neutral rating for the company in a research note on Wednesday, July 10th. HSBC boosted their target price on Kenvue from $20.00 to $21.00 and gave the stock a hold rating in a research note on Wednesday, May 8th. Sanford C. Bernstein began coverage on Kenvue in a research note on Thursday, April 11th. They set an underperform rating and a $18.00 target price for the company. William Blair began coverage on Kenvue in a research note on Wednesday, April 3rd. They set a market perform rating for the company. Finally, JPMorgan Chase & Co. decreased their target price on Kenvue from $23.00 to $22.00 and set an overweight rating for the company in a research note on Monday, July 22nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kenvue has a consensus rating of Hold and a consensus price target of $22.45.

Kenvue Stock Performance

Shares of KVUE opened at $18.69 on Thursday. The stock has a 50-day simple moving average of $18.59 and a 200-day simple moving average of $19.53. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The stock has a market capitalization of $35.79 billion, a PE ratio of 23.96, a PEG ratio of 2.05 and a beta of 1.40. Kenvue has a 1 year low of $17.67 and a 1 year high of $25.00.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.03. The business had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The company’s revenue was down 24.9% compared to the same quarter last year. On average, analysts predict that Kenvue will post 1.13 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th will be given a dividend of $0.205 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $0.82 annualized dividend and a yield of 4.39%. Kenvue’s payout ratio is 102.56%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KVUE. Mutual Advisors LLC increased its holdings in shares of Kenvue by 6.1% in the fourth quarter. Mutual Advisors LLC now owns 10,606 shares of the company’s stock valued at $228,000 after purchasing an additional 612 shares during the period. CVA Family Office LLC acquired a new position in shares of Kenvue in the fourth quarter valued at approximately $32,000. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Kenvue by 3.7% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 604,176 shares of the company’s stock valued at $13,008,000 after purchasing an additional 21,514 shares during the period. Schechter Investment Advisors LLC increased its holdings in shares of Kenvue by 54.6% in the fourth quarter. Schechter Investment Advisors LLC now owns 15,747 shares of the company’s stock valued at $339,000 after purchasing an additional 5,564 shares during the period. Finally, Planned Solutions Inc. acquired a new position in shares of Kenvue in the fourth quarter valued at approximately $27,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.